MARTA GÓMEZ ALMERÍA-rekin lankidetzan egindako argitalpenak (6)

2022

  1. TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy

    Journal of Medicinal Chemistry, Vol. 65, Núm. 2, pp. 1585-1607

2021

  1. Bip heterozigosity aggravates pathological deterioration in experimental amyotrophic lateral sclerosis

    International Journal of Molecular Sciences, Vol. 22, Núm. 22

  2. Inactivation of the CB2 receptor accelerated the neuropathological deterioration in TDP-43 transgenic mice, a model of amyotrophic lateral sclerosis

    Brain Pathology, Vol. 31, Núm. 6

  3. Preclinical investigation in neuroprotective effects of the gpr55 Ligand VCE-006.1 in experimental models of Parkinson’s disease and amyotrophic lateral sclerosis

    Molecules, Vol. 26, Núm. 24

  4. Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis

    British Journal of Pharmacology, Vol. 178, Núm. 6, pp. 1373-1387

  5. Tideglusib, a non-atp competitive inhibitor of gsk-3as a drug candidate for the treatment of amyotrophic lateral sclerosis

    International Journal of Molecular Sciences, Vol. 22, Núm. 16